Ren Yuyue, Li Xiaoyun, Wang Wei, He Wanting, Wang Jinghua, Wang Ying
The Second Affiliated Hospital of Harbin Medical University, Harbin, PR China.
The Second Affiliated Hospital of Harbin Medical University, Harbin, PR China.
Clin Lymphoma Myeloma Leuk. 2017 Jul;17(7):415-423. doi: 10.1016/j.clml.2017.05.010. Epub 2017 May 10.
Multiple myeloma (MM) is a heterogeneous disorder, encompassing several related entities that share the common characteristic of being composed of monoclonal plasma cells (PCs). MicroRNAs (miRNAs) are small noncoding RNAs that control the expression of many target messenger RNAs involved in normal cell functions. Two serum microRNAs, miRNA-720 and miRNA-1246, were found to have potential as diagnostic biomarkers in myeloma. Therefore, we investigated a possible correlation of peripheral blood (PB) miRNA expression with diagnosis and prognosis.
We measured the expression of PB miRNA-720 and miRNA-1246 in 60 newly diagnosed MM patients by quantitative real-time PCR analyses. And analysed the relationship about the expression levels of miRNAs with other clinical features.
The expression levels of PB miRNAs are significantly higher in myeloma patients compared to controls and do not change with age, gender, disease stage, hemoglobin, bone marrow PC percentage, β microglobulin, serum albumin, calcium serum, serum creatinine, and myeloma protein, and independent of the deletion of chromosome 13, suggesting that the expression levels of PB miRNA-720 and miRNA-1246 can be used as a diagnostic test for myeloma. We first discovered that increased expression of PB miRNA-720 and miRNA-1246 were associated with shorter progression-free survival, indicating poor prognosis.
Our study demonstrated that PB miRNA-720 and miRNA-1246 might act as a promoting factor in the development of MM and could be a diagnostic factor, therapeutic effect evaluator, and prognostic indicator in the prognosis of MM. The miRNAs have a significant value of appreciation of individual patients' behavior during the chemotherapy and evaluation the therapeutic strategies.
多发性骨髓瘤（MM）是一种异质性疾病，包含几个相关实体，其共同特征是由单克隆浆细胞（PC）组成。微小RNA（miRNA）是小的非编码RNA，可控制许多参与正常细胞功能的靶信使RNA的表达。发现两种血清miRNA，即miRNA - 720和miRNA - 1246，具有作为骨髓瘤诊断生物标志物的潜力。因此，我们研究了外周血（PB）miRNA表达与诊断和预后之间的可能相关性。
我们通过定量实时PCR分析测量了60例新诊断MM患者外周血miRNA - 720和miRNA - 1246的表达。并分析了miRNA表达水平与其他临床特征的关系。
与对照组相比，骨髓瘤患者外周血miRNA的表达水平显著更高，且不随年龄、性别、疾病分期、血红蛋白、骨髓PC百分比、β微球蛋白、血清白蛋白、血钙、血清肌酐和骨髓瘤蛋白而变化，并且与13号染色体缺失无关，这表明外周血miRNA - 720和miRNA - 1246的表达水平可作为骨髓瘤的诊断检测指标。我们首次发现外周血miRNA - 720和miRNA - 1246表达增加与无进展生存期缩短相关，提示预后不良。
我们的研究表明，外周血miRNA - 720和miRNA - 1246可能在MM的发生发展中起促进作用，并且可能是MM预后的诊断因素、治疗效果评估指标和预后指标。这些miRNA在评估个体患者化疗期间的行为和评估治疗策略方面具有重要价值。
